Tranilast

• Catalog No.: T0318
• CAS Number: 53902-12-8
• M. F.: C18H17NO5
• M. W.: 327.33128
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 2-[3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
• IUPAC Traditional name: tranilast
• Synonyms: Rizaben; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; SB-252218; 3,4-DAA; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid

DATABASE IDS

• CAS Number: 53902-12-8
• PubChem SID: 24278719
• MDL Number: MFCD00864787

PROPERTIES

• Empirical Formula (Hill Notation): C18H17NO5
• Purity: ≥98% (HPLC)
• Gene Information: human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)
• Apperance: white to beige powder
• Melting Point: 166.2-168.2 °C(lit.)
• Solubility: DMSO: >10 mg/mL
• Solubility: H2O: insoluble
• GHS Signal Word: Warning
• GHS Hazard statements: H302
• European Hazard Symbols: Harmful (Xn)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• Risk Statements: 22
• RTECS: DG8731000
• Safety Statements: 26-36
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.

Description (简体中文)

Biochem/physiol Actions
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.